US-based pharmaceutical company US WorldMeds announced on Friday that it has received the 2026 Vision of Hope Award from the Sarcoma Foundation of America (SFA).
The company was chosen for its commitment to bringing new treatment options to people living with sarcoma and the way the organisation has engaged with the community, incorporating the patient advocacy perspective into its regulatory and development efforts.
SFA previously presented the award to Adaptimmune in 2022 for its work developing TECELRA (afamitresgene autoleucel). US WorldMeds acquired TECELRA in 2025 and has continued that mission by working to secure the product's full FDA approval, while continuing to pursue new therapeutic opportunities for people living with sarcoma.
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
Okami Medical receives FDA approval for expanded indication of LOBO Vascular Occluder
Kedrion to be honoured at Premier's Supplier Innovation Celebration
Zydus and MSN announce US launch of generic Adempas (Riociguat Tablets)
FDA approves second Reykjavik manufacturing suite for AVT02
Ractigen Therapeutics reports positive first-in-human data for RAG-18 in Duchenne muscular dystrophy
AnnJi Pharmaceutical's AJ201 advances into pivotal Phase 3 trial for SBMA